ACOBIOM and Montpellier University Hospital: a partnership on heart failure (MeDIAGSTOLE project)
ACOBIOM, a company specialized in the identification of biomarkers and the development of innovative diagnostics, announces today the signature of a partnership with the Montpellier University Hospital concerning the MeDIAGSTOLE clinical research program.
This project (NCT04699890) aims to develop diagnostic tools for left ventricular heart failure with preserved ejection fraction (HF/pEF) and to participate in the implementation of personalized medicine for patients suffering from this form of heart failure (HF/pEF), which represents 50% of the cases of left ventricular heart failure.
Indeed, heart failure with preserved ejection fraction (HF/pEF) is a difficult condition to diagnose and manage clinically in the absence of targeted therapy.
The HF/pEF affects the elderly population with comorbidities such as hypertension, obesity, anemia, and atrial fibrillation.
In the absence of specific biological markers or biomarkers, its diagnosis is based on cardiac imaging, echocardiography, or catheterization to measure altered cardiac relaxation and filling. Different from heart failure with reduced ejection fraction (HF/rEF), this condition has strong medical and economic impacts, including repeated hospitalizations (Braunwald, 2015; Ponikowski et al., 2016).
The identification of new genetic and/or cellular biomarkers specific to HF/pEF, the focus of the MeDIAGSTOLE clinical research program, would be an important innovation for the management of patients with this subtype of heart failure.
Within the framework of this clinical research program, promoted by the University Hospital of Montpellier and led by the cardiology department of Pr Roubille, the University Hospital decided to entrust ACOBIOM with the molecular analyses by sequencing of blood samples from patients admitted to the University Hospital. These analyses will be done using the RNA-Seq technique associated with the company’s bioinformatics and biostatistics platform, the fruit of 20 years of research and know-how in RNA analysis. This work will make it possible to identify RNA biomarkers (coding and non-coding) specific to heart failure, to develop a future diagnosis and the implementation of personalized medicine for patients suffering from this type of heart failure.
This partnership between the cardiology department of the Montpellier University Hospital and ACOBIOM follows previous scientific collaborations that aimed at identifying patients with left ventricular heart failure using a combination of current biochemical markers coupled with clinical data. Thanks to the company’s expertise in data processing and its know-how in machine-learning (artificial intelligence), a computer classification tool has been developed to diagnose heart failure with preserved ejection fraction (HF/pEF). A scientific article presenting this work is currently being published.
To download the press release:
